Background and Aim: Self-expandable metal stents (SEMS) are used for non-resectable malignant gastric outlet obstruction (GOO). Studies of covered versus uncovered SEMS have yielded inconsistent results as a result of heterogeneity in design and patient population. We carried out a meta-analysis to compare covered and uncovered gastroduodenal SEMS.
INTRODUCTION

M
ALIGNANT GASTRIC OUTLET obstruction (GOO) is caused mainly by gastric or pancreatobiliary neoplasms. [1] [2] [3] [4] [5] GOO presents with uncomfortable symptoms, such as nausea, vomiting, and abdominal distension, leading to malnutrition and impaired quality of life. 1 Endoscopic placement of a self-expandable metal stent (SEMS) is widely accepted as non-surgical palliative treatment of non-resectable malignant GOO, 1, [6] [7] [8] [9] particularly in cases with poor prognosis. 10, 11 However, a substantial fraction of patients experiences SEMS occlusion as a result of tumor ingrowth and mucosal hyperplasia through the mesh wall. 8, [12] [13] [14] To overcome this drawback of uncovered SEMS, covered SEMS were developed, and investigators have sought the effectiveness of these stents on prolongation of stent patency. 7, [15] [16] [17] [18] The covering membrane prevents SEMS from being embedded into the cancerous lesion or intestinal mucosa and, therefore, covered SEMS have been associated with a higher risk of migration. 15, 19 Despite lower invasiveness compared with surgical bypass, 10, [20] [21] [22] [23] we occasionally encounter potentially lethal adverse events associated with SEMS including bleeding and gastrointestinal (GI) perforation. 6, 14, 19 A better understanding of differences in outcomes between covered and uncovered SEMS may help us to further improve clinical effectiveness of SEMS for GOO as a result of non-resectable cancers. However, there has been inconsistency between the results of previous studies, presumably owing to small sample sizes of individual studies, various types of SEMS used, or differences in underlying cancers. 16, 17, [24] [25] [26] [27] [28] We therefore conducted a meta-analysis of the literature to compare short-and long-term outcomes between covered and uncovered SEMS for non-resectable malignant GOO. Study outcomes included occurrence or causes of SEMS dysfunction, technical and clinical success, and adverse events. In addition, we systematically reviewed the recent knowledge on outcomes of gastroduodenal SEMS.
METHODS
Literature search
B ASED ON A systematic electronic search using MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL), we identified clinical studies published from each database's earliest available date to October 2016, in which outcomes were reported both for covered and uncovered SEMS for non-resectable malignant GOO. Two authors (T.H. and R.H.) independently participated in the literature search, study selection, and data extraction. Disagreements were resolved through discussion with a third author (Y.N.). Search terms included 'gastric outlet obstruction', 'gastroduodenal obstruction', 'duodenal obstruction', 'stent', 'gastroduodenal stent', and 'duodenal stent'. The search was limited to fully published articles in English and adult human studies. The search was not limited in terms of length of patient follow up. Bibliographies of the identified articles were further screened for additional eligible articles. Among the identified articles, studies including ≥20 patients per group were included. Studies were excluded if they included only patients with altered upper GI anatomy (i.e. Billroth-II or Roux-en-Y reconstruction) or those with potentially resectable cancer.
Data collection
Using a standardized data extraction form, the following data were collected from each study: study design, patient demographics, stent characteristics, stent outcomes, and outcome definitions. Primary outcome was gastroduodenal SEMS dysfunction, and was evaluated using the following pre-specified definitions. SEMS dysfunction was defined as a composite endpoint of symptomatic occlusion or migration of a gastroduodenal stent. Time to SEMS dysfunction (TTD) was defined as time between gastroduodenal SEMS placement and stent dysfunction. There was inconsistency of the definitions of SEMS dysfunction and TTD across studies (Table S1 ). We also collected data on causes of SEMS dysfunction (i.e. occlusion [ingrowth, overgrowth, food impaction, fracture, etc.] or migration). Secondary outcomes included technical and clinical success rates, the gastric outlet obstruction scoring system (GOOSS) score after the procedure, 29 and adverse events. As described elsewhere, 29 the GOOSS score was graded as 0 (no oral intake), 1 (liquids only), 2 (soft solid diet), or 3 (low-residue or full diet). We dichotomized the post-procedural GOOSS score as 0-1 versus 2-3 for comparison between covered and uncovered SEMS. We used the investigators' original definitions for technical and clinical success (Table S2) . Adverse events were defined when patients underwent SEMS-related manifest symptoms, additional care or prolonged hospitalization. We excluded temporary abdominal pain after SEMS placement in the analysis of adverse events, because this adverse event was supposed to be substantial, but not described in most studies. Causes of SEMS dysfunction and adverse events were relabeled as appropriate, rather than as the investigators' original definitions (e.g. when SEMS occlusion and migration were analyzed as adverse events, they were treated as SEMS dysfunction in the current analysis).
Statistical analysis
Using the data reported in the pooled studies, summary risk ratios (RR) of binary outcome variables were computed using the Mantel-Haenszel fixed-effect model. 30 Statistical heterogeneity between studies was assessed by the Q and I 2 statistics. 31 For the Q-statistic, we used a P-value of 0.10 for statistical significance in view of the low power of tests for heterogeneity. 32 The I 2 statistics of approximately 25%, 50%, and 75% were considered as low-, moderate-, and high-level heterogeneity, respectively. 33 When there was evidence for statistically significant heterogeneity between studies, we used the DerSimonian-Laird random-effects model. 34 Among the included studies, the hazard ratio (HR) of stent dysfunction for covered versus uncovered SEMS was reported in two studies only, 16, 25 and the indirect estimation of the natural logarithm of the HR and its variance using survival probabilities based on the KaplanMeier method or a P-value for the log-rank test 35 seemed not to provide robust predictions for some of the included studies. Therefore, we did not conduct a meta-analysis using actual or estimated HR of SEMS dysfunction. We calculated 95% confidence interval (CI) for each outcome variable. We assessed potential publication bias by means of the funnel plot with Begg's rank correlation test 36 and Egger's linear regression test. 37 We carried out sensitivity analyses limited to five randomized controlled trials (RCT) or excluding studies which included fully covered SEMS. A two-sided P-value <0.05 was considered statistically significant, unless indicated otherwise. All analyses were carried out using R software version 3.3.1 and the meta package (R Development Core Team; http://www.r-project.org).
RESULTS
W
E IDENTIFIED 13 eligible studies (five RCT, 16, 17, [24] [25] [26] one prospective study, 38 and seven retrospective studies 27, 28, [39] [40] [41] [42] [43] ; Figure 1 ; Table 1 ). 44 A total of 1624 patients who underwent endoscopic gastroduodenal SEMS placement under fluoroscopic guidance between 1998 and 2015 were analyzed. Gastric cancer was most common as the primary cancer (1051 patients, 65%), followed by pancreatic cancer (335 patients, 21%). Characteristics of gastroduodenal SEMS used in the pooled studies are summarized in Table 2 . There were 688 and 800 patients who received covered and uncovered SEMS, respectively. Most SEMS were made of nitinol, an alloy of nickel and titanium, and most covering membranes were silicone or polytetrafluoroethylene. In one RCT, covered SEMS were placed fluoroscopically alone as a protocol. 17 One retrospective study included 15 patients with Billroth-II anastomosis (11%), 39 and another one included 18 patients with anastomotic obstruction (7.1%). 43 In two retrospective studies, both partially and fully covered types were used as covered SEMS. 27, 42 As the primary outcome, we evaluated rates of gastroduodenal SEMS dysfunction based on 13 studies (Fig. 2) . 16, 17, [24] [25] [26] [27] [28] [38] [39] [40] [41] [42] [43] Compared with uncovered SEMS, covered SEMS were not associated with the risk of stent dysfunction (summary RR, 1.02; 95% CI, 0.79-1.32), but there was evidence on between-study heterogeneity (P heterogeneity = 0.024, I 2 = 49%; Fig. 2A ). When we included five RCT, 15, 16, [24] [25] [26] covered SEMS, compared with uncovered SEMS, were associated with a lower risk of stent dysfunction (summary RR, 0.63; 95% CI, 0.45-0.88) with no evidence on between-study heterogeneity (P heterogeneity = 0.41, I 2 = 0%; Fig. 2B ). Considering that inclusion of fully covered SEMS might have influenced the summary RR of occlusion or migration, we conducted a sensitivity analysis excluding two studies which included fully covered SEMS, 27, 42 but yielded similar results (data not shown). There was no evidence on publication bias in rates of SEMS dysfunction (P Begg = 0.90 and P Egger = 0.88). According to the recommendations elsewhere, 45 we did not conduct the Begg's or Egger's test for sensitivity analyses limited to <10 studies. In the funnel plot for all studies, there was only one study out of the 95% confidence limits (Fig. S1) .
As secondary analyses, we evaluated causes of SEMS dysfunction based on 13 studies (Fig. 3) . 16, 17, [24] [25] [26] [27] [28] [38] [39] [40] [41] [42] [43] Compared with uncovered SEMS, covered SEMS were associated with a lower risk of stent occlusion (summary RR, 0.44; 95% CI, 0.28-0.68; P heterogeneity = 0.020, I 2 = 50%), but with a higher risk of stent migration (summary RR, 4.28; 95% CI, 2.89-6.34; P heterogeneity = 0.55, I 2 = 0%). Owing to a small number of studies which specifically reported causes of stent occlusion (ingrowth, overgrowth, food impaction etc.), we did not further investigate the characteristics of causes of occlusion in covered and uncovered SEMS. Sensitivity analyses which included five RCT 15, 16, [24] [25] [26] yielded similar results (summary RR for stent occlusion, 0.19; 95% CI, 0.10-0.37; P heterogeneity = 0.65, I 2 = 0%; and summary RR for stent migration, 4.00; 95% CI, 1.80-8.86; P heterogeneity = 0.67, I 2 = 0%). We evaluated technical and clinical success of gastroduodenal SEMS placement (Fig. S2 ). Three studies did not describe group-specific rates of technical success, 39, 41, 42 and one study did not define clinical success. 39 Crude rates of technical success reported in 10 studies were >91% and >96% for covered and uncovered SEMS, respectively; 16, 17, [24] [25] [26] [27] [28] 38, 40, 43 and those of clinical success reported in 12 studies were >82% and >75%, respectively. 16, 17, [24] [25] [26] [27] [28] 38, [40] [41] [42] [43] Weighted rates of technical and clinical success did not differ significantly between covered and uncovered SEMS (Fig. S2A ,B, respectively). Raw GOOSS score after gastroduodenal SEMS placement was available in seven 29 (12%) † Data are expressed as number of patients (%). ‡ Number of cases of the intention-to-treat population including cases excluded from the analysis. § Origin of cancer was not specifically described for 100 pancreatobiliary cancers. GOO, gastric outlet obstruction; RCT, randomized controlled trial; SEMS, self-expandable metal stent. studies. [25] [26] [27] [28] 38, 41, 43 Weighted rates of the GOOSS score ≥2 after the procedure were not different between the groups (Fig. S2C) , although there was inconsistency of the timing to determine the post-procedural scores (Table S2) .
We evaluated adverse events associated with gastroduodenal SEMS based on 12 studies (Fig. 4) . 16, 17, [24] [25] [26] [27] [28] 38, [40] [41] [42] [43] One study did not describe group-specific rates of adverse events. 39 Compared with uncovered SEMS, covered SEMS appeared to be associated with a higher risk of overall adverse events (summary RR, 1.75; 95% CI, 1.09-2.83; P heterogeneity = 0.37, I 2 = 7.5%). Excluding cases with minimal bleeding which were supposed to have no drop in we conducted a meta-analysis of 13 published studies. The present study suggested no significant difference in stent dysfunction rates between the groups. In line with prior series, 15, 19 covered SEMS dysfunction was characterized by lower occlusion and higher migration risks. As the present study found a potentially higher risk of adverse events in covered SEMS, further investigation is warranted to confirm the safety of prolonged placement of covered SEMS in the upper GI tract. Figure 2 Meta-analysis of dysfunction rates of covered and uncovered self-expandable metal stents (SEMS) for non-resectable malignant gastric outlet obstruction (a, all studies; b, randomized controlled trials). Risk ratio (RR) of stent dysfunction for covered SEMS compared with uncovered SEMS is presented for each study (center of gray square) with 95% confidence interval (CI; horizontal line). Summary RR using a meta-analysis is presented at the bottom of each panel (black diamond) with 95% CI (upper and lower limits). P-value for the Q-statistic for between-study heterogeneity is shown. W, weight.
Study
Random effects model
Compared with surgical gastrojejunostomy with significant morbidity, successful SEMS placement for malignant GOO can facilitate early resumption of oral intake, timely initiation of anticancer treatment and, most importantly, improve patients' quality of life. 10, [20] [21] [22] [23] However, a fraction of GOO patients cannot benefit from SEMS placement, and there are several serious adverse events associated with the procedure. In addition to SEMS development focusing on dysfunction causes specific Figure 3 Meta-analyses of rates of occlusion or migration in covered and uncovered self-expandable metal stents (SEMS) for non-resectable malignant gastric outlet obstruction (a, SEMS occlusion; b, SEMS migration). Risk ratio (RR) of occlusion or migration for covered SEMS compared with uncovered SEMS is presented for each study (center of gray square) with 95% confidence interval (CI; horizontal line). Summary RR using a meta-analysis is presented at the bottom of each panel (black diamond) with 95% CI (upper and lower limits). P-value for the Q-statistic for between-study heterogeneity is shown. W, weight.
Digestive
for covered or uncovered SEMS, patient selection based on expected benefits from SEMS placement is required to improve clinical outcomes of gastroduodenal SEMS.
Gastroduodenal SEMS dysfunction
Covered SEMS for malignant GOO have been recognized as a 'two-bladed sword', which can minimize the risk of stent occlusion as a result of tumor ingrowth, but may increase the risk of stent migration. 15, 19 Reduction of the dysfunction risk in covered SEMS was suggested in the subgroup analysis of RCT, but not in the analysis of all studies. Migration rates of covered SEMS in the included RCT were reasonably low with a range of 6-14%, 16, 17, 25, 26 except for 26% in one RCT. 24 The covered SEMS used in those studies were characterized by antimigration configuration (i.e. low axial force, 25, 26 a proximal end tailored to fit the gastric outlet, 17 and bumpy shape with varying radial force along the axis). 16 Some investigators have sought methods of mechanical prevention for stent migration including coaxial placement of a covered SEMS in an uncovered SEMS 46 and anchoring by endoscopic clipping; 47 however, there have been no established methods to prevent stent migration. Therefore, efforts to develop covered SEMS with better conformability are needed to improve the outcomes of covered SEMS for malignant GOO.
Heterogeneity of SEMS dysfunction rates between RCT and retrospective studies might also be explained by treatment selection bias. Covered SEMS placement across the ampulla may predispose patients to risk of cholangitis or pancreatitis as a result of obstruction of the orifice and was likely avoided. 40, [48] [49] [50] Indeed, among the included RCT, three included gastric cancer patients only, 16, 17, 24 and one excluded patients with duodenal obstruction involving the periampullary lesion. 25 Retrospective series suggested that SEMS placement apart from the ampulla (the gastric outlet or distal duodenum) might be associated with a higher risk of stent migration or occlusion compared with SEMS placement across the ampulla. 42, 51 Predictive factors for gastroduodenal SEMS dysfunction have been reported. Chemotherapy after uncovered SEMS placement has been associated with longer stent patency as a result of prevention of local tumor progression, 16, [52] [53] [54] [55] although interpretation of these findings may need caution to potential bias derived from the between-group difference in the baseline hazard of cancer-related death. [56] [57] [58] Figure 4 Meta-analysis of overall adverse events associated with covered and uncovered self-expandable metal stents (SEMS) for non-resectable malignant gastric outlet obstruction. Risk ratio (RR) of overall adverse events for covered SEMS compared with uncovered SEMS is presented for each study (center of gray square) with 95% confidence interval (CI; horizontal line). Summary RR using a meta-analysis is presented at the bottom (black diamond) with 95% CI (upper and lower limits). P-value for the Q-statistic for between-study heterogeneity is shown. W, weight.
increase the risk of covered SEMS migration. [52] [53] [54] Taken together, patients receiving intensive chemotherapy may be good candidates for uncovered SEMS. A retrospective study identified impaired patient performance status as a potential risk factor for stent dysfunction. 59 Patients with impaired performance status generally have poor prognosis, and adverse events associated with SEMS placement tend to be lethal for those patients. Therefore, further investigation of the indication for gastroduodenal SEMS is warranted taking into account expected survival time. Given the promising results of covered SEMS with specific configuration, the association of mechanical SEMS properties (e.g. radial and axial force [60] [61] [62] [63] ) with stent occlusion or migration is also warranted.
Technical success, clinical success, and GOOSS score after SEMS placement
The present study suggested that there might be no difference in technical success between covered and uncovered SEMS. The initial and crucial step of SEMS placement for malignant GOO is to pass a guidewire through a cancerous obstruction. A major advantage of endoscopic SEMS placement is that, once the wire is fully passed over the obstruction, the delivery system of either a covered or an uncovered SEMS can be readily advanced over the wire using a mechanical support by an endoscope. 64 Through-the-scope delivery systems used in current clinical practice may permit smooth deployment of both SEMS types. Therefore, technical failure of SEMS placement attributes mostly to difficulties in passing a guidewire, deformity of the upper GI tract, looping of the delivery system, or stent malposition during deployment, rather than as a difference between the types of SEMS. 19 The present study did not find a significant difference between covered and uncovered SEMS in either clinical success or the GOOSS score after duodenal SEMS placement. These findings support no between-group difference in stent expansion and food passage immediately after SEMS deployment. Short-term clinical outcomes may depend on other factors such as impaired patient performance status, multifocal GI tract obstruction, long obstruction, insufficient stent expansion, carcinomatosis, ascites, and functional GOO as a result of tumor neural involvement. 43, 59, 65, 66 Adverse events
Severe adverse events associated with gastroduodenal SEMS placement include bleeding, GI perforation, cholangitis, and pancreatitis. 6, 14, 19 In the present study, a trend toward a higher rate of overall adverse events in covered SEMS was observed. When we excluded cases with minimal bleeding, which was unlikely clinically significant, overall rates of adverse events did not differ between the groups. As for bleeding, 67 some investigators have sought the effectiveness of covered SEMS on hemostasis for hypervascular tumors of the GI tract 68, 69 and, therefore, we suppose that covered SEMS may not contribute to the increased risk of bleeding. Procedure-related GI perforation may be caused by manipulation of a guidewire and catheter, 70, 71 advancement of the delivery system, 48 and excess balloon dilation before/after SEMS deployment. 7 SEMS-related GI perforation may be as a result of contact of a SEMS edge, secondary SEMS placement, migration of a SEMS or its fracture, placement of multiple SEMS in a single session, and so forth. 19, 59 The covering membrane along with mechanical compression to the ampulla by SEMS may cause obstructive jaundice, cholangitis, or pancreatitis. 40, [48] [49] [50] In addition, non-resectable malignant GOO is often complicated by biliary obstruction as a result of tumor involvement. [2] [3] [4] [5] In cases with a biliary stent in situ, duodenal tumor invasion can be a risk factor for biliary stent dysfunction as a result of enhanced duodenobiliary reflux. 5, 72, 73 Given the feasibility of endoscopic ultrasound-guided transmural biliary drainage including choledochoduodenostomy and hepaticogastrostomy in patients with an indwelling duodenal SEMS, [74] [75] [76] concern with biliary obstruction might be minimal in current clinical practice, but attention should be paid to avoid SEMS-related pancreatitis.
48,49
Limitations
One major limitation of the present study was that we evaluated SEMS dysfunction as a binary outcome variable, but not as a time-to-event variable, because HR of gastroduodenal SEMS dysfunction were often unavailable. However, given the poor prognosis of patients with nonresectable malignant GOO, RR for gastroduodenal SEMS dysfunction during follow-up time was supposed to serve as a surrogate endpoint for HR of SEMS dysfunction. In addition, owing to small sample sizes, Kaplan-Meier curves of dysfunction of covered and uncovered SEMS occasionally crossed, suggesting violation of proportional hazard assumption and potentially compromising HR calculation. Therefore, a standardized reporting system as reported elsewhere [77] [78] [79] needs to be developed for better evaluation and comparison of gastroduodenal SEMS. We conducted a meta-analysis based on pooled studies in the literature and
did not use individual patient data. Finally, there was between-study heterogeneity in SEMS types, primary cancers, study design, and inclusion criteria.
Conclusions and future perspectives
The present study found no significant difference in clinical effectiveness between covered and uncovered SEMS for malignant GOO, but characterized the causes of stent dysfunction (i.e. migration and occlusion were more common in covered and uncovered SEMS, respectively). Antimigration systems in covered SEMS and tailored management based on risk factors for stent dysfunction would help improve outcomes of gastroduodenal SEMS. Recently, endoscopic ultrasound-guided gastrojejunostomy for malignant GOO was reported as an alternative to endoscopic SEMS placement or surgical bypass, potentially possessing longer patency as a result of insusceptibility to tumor invasion. 80, 81 An investigation of those modalities for malignant GOO, taking into account patient survival and quality of life, and cost-effectiveness, is warranted. 
SUPPORTING INFORMATION
A DDITIONAL SUPPORTING INFORMATION may be found in the online version of this article at the publisher's web site. Figure S1 . Funnel plot to examine potential publication bias in risk ratios of stent dysfunction for covered vs. uncovered SEMSs for nonresectable malignant gastric outlet obstruction. Figure S2 . Meta-analyses of short-term outcomes of covered and uncovered SEMSs for nonresectable malignant gastric outlet obstruction (A, technical success; B, clinical success; and C, the gastric outlet obstruction scoring system score ≥2 after SEMS placement). Table S1 . Definitions of dysfunction of a SEMS for nonresectable malignant gastric outlet obstruction and time to dysfunction in the studies included in a meta-analysis. Table S2 . Definitions of technical and clinical success of a SEMS for nonresectable malignant gastric outlet obstruction in the studies included in a meta-analysis.
